Serum Gamma-glutamyl Transferase Levels Predict Functional Outcomes after Aneurysmal Subarachnoid Hemorrhage

Objective We aim to explore the potential association between serum gamma-glutamyl transferase levels and functional outcome after aneurysmal subarachnoid hemorrhage in a Chinese population. Methods A total of 386 aneurysmal subarachnoid hemorrhage patients were included in the study from September 2007 to February 2015. Baseline serum gamma-glutamyl transferase levels and 6-month follow-up functional outcomes were determined. A poor outcome was defined as a modified ranking scale score of ≥ 3. The multivariable logistic model was used to analyze the relationship between serum gamma-glutamyl transferase and clinical outcomes after aneurysmal subarachnoid hemorrhage. Results The adjusted poor outcome rates of patients with gamma-glutamyl transferase levels of 〈 30 U/L, 30-50 U/L and ≥ 50 U/L were 16.7%, 19.6%, and 34.4%, respectively （P 〈 0.01）. The age-sex and multivariable adjusted odds ratios （95% confidence intervals） of poor prognosis comparing the top group （≥ 50 U/L） with the lowest group （〈 30 U/L） were 5.76 （2.74-12.13）, 6.64 （2.05-21.52）, and 6.36 （1.92-21.02）. A significant linear trend existed between gamma-glutamyl transferase level and aneurysmal subarachnoid hemorrhage prognosis. This association was also observed among nondrinkers. Conclusion Patients with higher gamma-glutamyl transferase levels were more likely to have a poor prognosis. Serum gamma-glutamyl transferase can be considered to be an independent predictor of functional outcomes after aneurysmal subarachnoid hemorrhage.

Association of serum gamma-glutamyl transferase with treatment outcome in chronic hepatitis B patients

AIM:To investigate the association of serum gammaglutamyl transferase(GGT) levels with chronic hepatitis B infection and hepatitis B e antigen(HBe Ag) seroconversion.METHODS:A retrospective study was performed on clinical data collected from patients who had been positive for hepatitis B surface antigen for > 6 mo and who were antiviral-treatment na?ve(n = 215) attending the Hepatitis Clinic at Nanjing Drum Tower Hospital between August 2010 and December 2013. Healthy individuals without liver disease(n = 83) were included as controls. Patients were categorized into four groups based on disease status as recommended by the European Association for the Study of the Liver:immune tolerance(IT; n = 47),HBe Ag-positive hepatitis(EPH; n = 93),HBe Ag-negative hepatitis(ENH;n = 20),and inactive carrier(IC; n = 55). Prediction of complete response(CR) based on serum GGT was also examined in EPH patients(n = 33) treated for 48 wk with nucleos(t)ide analogue(NA) therapy,including lamivudine plus adefovir combination therapy(n = 20) or entecavir monotherapy(n = 13). CR was defined as a serum hepatitis B virus DNA level < 500 copies/m L and HBe Ag seroconversion by 48 wk of treatment. RESULTS:Serum GGT levels were significantly increased in EPH and ENH patients relative to the IT,IC,and healthy control groups(P < 0.01 for all). However,no significant difference in serum GGT levels was found between the EPH and ENH groups. Baseline serum GGT levels were significantly higher in patients who achieved CR(7/33; 21.2%) compared to patients in the non-CR group(26/33; 78.8%; P = 0.011). In addition,the decline in serum GGT was greater in CR patients compared to non-CR patients after 24 wk and 48 wk of treatment(P = 0.012 and P = 0.008,respectively). The receiver operating characteristic curve yielded a sensitivity of 85.71% and a specificity of 61.54% at a threshold value of 0.89 times the upper limit of normal for baseline serum GGT in the prediction of CR following NA therapy. CONCLUSION:Serum GGT is significantly elevated in EPH and ENH patients and is a potential biomarker for the prediction of HBe Ag seroconversion following NA therapy.

The Micro-determination of Serum Gamma-Glutamyl Transferase

The method of serum gamma-glutamyl transferase colorimeter assay was modified by changing the wave length from 420 nm to 400 nm, the incubated temperature from 37℃ to 50℃, the sample amount from 30 μl to 6μl. The modified method was proved to be more sensitive, with CV of intra-group being 2. 06% and accuracy 97. 4%. The method is suitable for clinical application with small-amount blood samples collected frorri earlobe or finger tip.

Gamma-glutamyl transferase 5 overexpression in cerebrovascular endothelial cells improves brain pathology,cognition,and behavior in APP/PS1 mice

In patients with Alzheimer’s disease,gamma-glutamyl transferase 5(GGT5)expression has been observed to be downregulated in cerebrovascular endothelial cells.However,the functional role of GGT5 in the development of Alzheimer’s disease remains unclear.This study aimed to explore the effect of GGT5 on cognitive function and brain pathology in an APP/PS1 mouse model of Alzheimer’s disease,as well as the underlying mechanism.We observed a significant reduction in GGT5 expression in two in vitro models of Alzheimer’s disease(Aβ_(1-42)-treated hCMEC/D3 and bEnd.3 cells),as well as in the APP/PS1 mouse model.Additionally,injection of APP/PS1 mice with an adeno-associated virus encoding GGT5 enhanced hippocampal synaptic plasticity and mitigated cognitive deficits.Interestingly,increasing GGT5 expression in cerebrovascular endothelial cells reduced levels of both soluble and insoluble amyloid-βin the brains of APP/PS1 mice.This effect may be attributable to inhibition of the expression ofβ-site APP cleaving enzyme 1,which is mediated by nuclear factor-kappa B.Our findings demonstrate that GGT5 expression in cerebrovascular endothelial cells is inversely associated with Alzheimer’s disease pathogenesis,and that GGT5 upregulation mitigates cognitive deficits in APP/PS1 mice.These findings suggest that GGT5 expression in cerebrovascular endothelial cells is a potential therapeutic target and biomarker for Alzheimer’s disease.

Serum Gamma-glutamyl Transferase Concentration Within the Reference Range is Related to the Coronary Heart Disease Risk Prediction in Korean Men： Analysis of the Korea National Health and Nutrition Examination Survey （V-1, 2010 and V-2, 2011）

Background：Limited data exist on the association of serum gamma-glutamyl transferase （GGT） level within the reference range with the increased risk of coronary heart disease （CHD） prediction in men.The study examined the association between serum GGT concentration within the reference range and the CHD risk prediction in Korean men.Methods：The study employed data from Korean National Health and Nutrition Examination Survey （V-1,2010 and V-2,2011） where a total of 1301 individuals were analyzed.A 10-year CHD risk prediction was computed using the Framingham Risk Score （FRS） modified by the National Cholesterol Education Program （NCEP） Adult Treatment Panel Ⅲ （ATP Ⅲ）.Results：Positive correlations were established between log-transformed GGT concentration and FRS （r =0.237,P 〈 0.001）.After adjustment of body mass index,the amount of alcohol intake and low-density lipoprotein-cholesterol,the odds ratio （95% confidence interval） for intermediate risk and beyond of 10-year CHD prediction （10-year risk ≥10%） with lowest quartile of participants was 1.21 （0.78-1.87） for second quartiles,1.39 （0.88-2.21） for third quartiles and 2.03 （1.23-3.34） for highest quartiles.Conclusions：Higher serum GGT within its reference range was significantly correlated with a 10-year CHD risk prediction estimation using NCEP ATP Ⅲ in Korean men.

Effect of <i>Lactobacillus brevis</i>SBC8803 on Gamma-Glutamyl Transferase in Japanese Habitual Drinkers: A Double-Blind, Placebo-Controlled Study

A randomized, double-blind, placebo-controlled clinical trial in Japanese habitual drinkers was conducted to evaluate the efficacy of Lactobacillus brevis SBC8803 to alleviate adverse effect of alcohol. Subjects who drank habitually and had moderately higher levels of gamma-glutamyl transferase (GGT) (50 - 100 IU/L) were enrolled. The levels of transaminases in these subjects were almost within normal levels (aspartate transaminase (AST) <30 IU/L and alanine transaminase (ALT) <40 IU/L). Either the capsules containing placebo (n = 23) or 130 mg (4.0 × 1010 colony-forming units) of live L. brevis SBC8803 (n = 22) per day were administered for the continuous eight weeks (56 days). During the period, the subjects both in test group and placebo groups have kept each drinking behavior as usual. Regarding lipid metabolism, triacylglycerol (TG) levels in the male test group significantly decreased at week 4 as compared with week 0. Biomarkers of hepatocytes-damage;AST and ALT levels showed no significant differences between the pla- cebo and test groups at both weeks 4 and 8. Oxidative stress marker;GGT at weeks 4 was significantly lower in the test group than that in the placebo group (p = 0.017), but not at weeks 8. However, taking a reduced rate of GGT at weeks 8 comparing with that at week 0, that in the test group showed larger value comparing with that in the placebo group. These data about TG and GGT suggest that, although efficacy of L. brevis SBC8803 is limited in this study, intake of the probiotic may alleviate alcoholic influence in lipid metabolism and oxidative stress.

Oxidative stress-elevated high gamma glutamyl transferase levels, and aging, intake of tropical food plants, migration and visual disability in Central Africans

·AIM:To investigate the independent pathogenic role of high serum gamma-glutamyl transferase (GGT) levels, sociodemographic data, dietary and environmental risk factors for visual disability (VD). ·METHODS:This was a case-control study, run in 200 black Congolese patients managed in Saint Joseph Hospital Ophthalmology Division from Kinshasa town. Logistic regression model was used to identify determinants of VD (n = 58) among sex, age, cigarette smoking, alcohol abuse, rural-urban migration, education levels, aging ≥60 years, intake of red Beans, Safou fruit and Taro leaves, lipid profile, residence, socioeconomic status, and GGT. ·RESULTS:After adjusting for confounding factors, we identified migration (OR=3.7 95% CI:1.2-11.3; P =0.023), low education level (OR=3.1 95% CI 1.1-8.5; P =0.026), no intake of Safou fruit (OR=34.2 95% CI 11.5-102; P < 0.0001), age ≥60 years (OR=2.5 95% CI 1.01-6.5; P = 0.049), and serum GGT ≥10U/L (OR=3.6 95% CI 1.3-9.6; P = 0.012) as the significant and independent determinants of VD. ·CONCLUSION:VD appears as a major public health problem in Central Africa to be prevented or delayed by control of migration, lifestyle changes, antioxidant supplements, appropriate diet, nutrition education, and blocking of oxidative stress.

Aspartate transferase-to-platelet ratio index-plus: A new simplified model for predicting the risk of mortality among patients with COVID-19

BACKGROUND Coronavirus disease 2019(COVID-19)has a spectrum of clinical syndromes with serious involvement of the lung and frequent effection of the liver and hemostatic system.Blood biomarkers are affordable,rapid,objective,and useful in the evaluation and prognostication of COVID-19 patients.AIM To investigate the association between aspartate transferase-to-platelet ratio index(APRI)and in-hospital mortality to develop a COVID-19 mortality prediction model.METHODS A multicenter cohort study with a retrospective design was conducted.Medical records of all consecutive adult patients admitted to Al-Azhar University Hospital(Assiut,Egypt)and Chest Hospital(Assiut,Egypt)with confirmed COVID-19 from July 1,2020 to October 1,2020,were retrieved and analyzed.The patient cohort was classified into the following two categories based on the APRI:(1)COVID-19 presenting with APRI≤0.5;and(2)COVID-19 presenting with APRI(>0.5 and≤1.5).The association between APRI and all-cause in-hospital mortality was analyzed,and the new model was developed through logistic regression analyses.RESULTS Of the 353 patients who satisfied the inclusion criteria,10%were admitted to the intensive care unit(n=36)and 7%died during the hospital stay(n=25).The median age was 40 years and 50.7%were male.On admission,49%had aspartate transferase-dominant liver injury.On admission,APRI(>0.5 and≤1.5)was independently associated with all-cause in-hospital mortality in unadjusted regression analysis and after adjustment for age and sex;after stepwise adjustment for several clinically relevant confounders,APRI was still significantly associated with all-cause inhospital mortality.On admission,APRI(>0.5 and≤1.5)increased the odds of mortality by fivetimes(P<0.006).From these results,we developed a new predictive model,the APRI-plus,which includes the four predictors of age,aspartate transferase,platelets,and serum ferritin.Performance for mortality was very good,with an area under the receiver operating curve of 0.90.CONCLUSION APRI-plus is an accurate and simplified prediction model for mortality among patients with COVID-19 and is associated with in-hospital mortality,independent of other relevant predictors.

云南地区53例先天性高胆红素血症临床特征及UGT1A1基因多态性分析

目的探讨云南地区53例UGT1A1基因突变所致的先天性高胆红素血症(Gilbert综合征、Crigler-Najjar综合征)的临床特征及UGT1A1基因突变特点。方法选取2017年1月至2022年12月间昆明市儿童医院消化内科53例Gilbert综合征(GS组)、Crigler-NajjarⅡ型综合征(CN-2组)患儿的临床数据、UGT1A1基因突变结果,回顾性分析患儿的临床特征、实验室检查结果和基因多态性。结果少数民族患儿均在2组中发病率较高,CN-2组中女性比例比GS高。肝脏系统方面,CN-2组TBil、IDB水平较GS组更高,差异均有统计学意义(P<0.05),GS组肝脏结构正常,CN-2组有3例患者肝胆结构有异常。肝外系统方面,血液系统、糖代谢无异常,血脂、甲状腺功能代谢有异常,GS组有维生素D不足,CN-2组存在维生素A、D缺乏及维生素E水平下降。2组患儿均存在心脏结构异常,但CN-2组较GS组发病率高。在所有患者中,突变频率最高的为发生在5号外显子上的c.1456T>G(32例,60.37%),其次为c.1091C>T(14例,26.42%)、1号外显子c.211G>A(6例,11.32%)和c.1198A>C(4例,7.55%)。c.1456T>G位点突变在GS组和CN-2组的频率分别为69.23%和57.5%(9例和23例),2组间差异无统计学意义(P>0.05)。2组中,其次突变频率较高的为c.1091C>T(4例和10例),2组间差异无统计学意义(P>0.05)。UGT1A1基因单倍型1、3、4在GS组和CN-2组间的频率差异均有统计学意义(P<0.05)。UGT1A1基因的4种主要突变形式,在性别和不同民族间,差异无统计学意义(P>0.05)。结论GS组和CN-2组在肝脏系统、肝外系统的临床表现存在不同,UGT1A1基因突变频率最高的为发生在5号外显子上的c.1456T>G。

血清镁离子浓度与直肠癌患者谷氨酰转肽酶的关系

直肠癌患者血清镁离子(Mg^(2+))浓度对γ-谷氨酰转肽酶(γ-GT)的影响尚不明确,收集分析临床数据,Mg^(2+)浓度不呈正态分布(D=0.737,P<0.05),按照中位数分组,比较不同组间临床病理特征的差异,用局部加权散点平滑(LOWESS)、分段线性回归方法,拟合血清Mg^(2+)浓度与γ-GT的关系。结果发现,与Mg^(2+)浓度小于0.92 mmol/L组的直肠癌患者比较,Mg^(2+)浓度≥0.92 mmol/L组的γ-GT和血清总胆固醇较高(P均<0.05)。LOWESS的结果表明,原始数据中血清Mg^(2+)浓度的两个变化点分别为0.92 mmol/L和0.99 mmol/L,自然对数转换的数据中血清Mg^(2+)浓度的另外两个变化点分别为-0.167和-0.01。利用原始数据建立的两段线性回归模型表明,血清Mg^(2+)浓度的变化点为0.98 mmol/L,Mg^(2+)浓度<0.98 mmol/L对γ-GT有正向影响,Mg^(2+)≥0.98 mmol/L时有负向影响。另一个使用自然对数转换数据的两段线性回归模型显示,血清Mg^(2+)浓度的变化点为0.01,其中Mg^(2+)浓度的自然对数<0.01对γ-GT有正向影响,当Mg^(2+)浓度的自然对数≥0.01时则有负向影响。用原始数据LOWESS回归的2个拐点,即0.92 mmol/L和0.99 mmol/L的Mg^(2+)浓度,进行三段线性回归分析,结果显示,<0.980 mmol/L的Mg^(2+)浓度,对γ-GT的影响是正向的,且与<0.929 mmol/L的Mg^(2+)浓度区间的系数不同,影响程度不同,而在≥0.980 mmol/L的Mg^(2+)浓度区间,对γ-GT的影响是负向的,此外,用对数转换数据LOWESS的2个拐点进行的三段线性回归,也显示Mg^(2+)浓度的自然对数以-0.020为分界点时,对γ-GT的影响方向是相反的,但三段线性回归模型均没有统计学意义,总之,具有较高Mg^(2+)浓度的直肠癌患者,其γ-GT的水平也较高,Mg^(2+)浓度对γ-GT的影响存在拐点效应,为γ-GT的关联因素研究提供了基础。

藏红花红O对家兔谷胱甘肽S-转移酶亚型活性的影响

目的 :观察藏红花红O对家兔血清、尿谷胱甘肽S 转移酶 (GST)及亚型α、μ、π活性的影响。方法 :家兔静脉注射藏红花红O建立肾损模型 ,采用紫外分光光度法连续动态测定血中GST及其亚型α、μ、π活性。同时与尿GST亚型活性及血尿素氮 (BUN)水平进行比较。结果 :血清、尿GST均于给药 6h后开始升高 ,12h升至最高。血GST π也于给药 6h后升高 ,9h升至最高 ,达正常对照的 3.5倍 (P <0 .0 5 )。尿GST π、尿GST α与其改变基本一致。血清及尿GST μ均无明显改变。血BUN于 15h开始升高 ,此后持续升高并维持在高水平上 ,且与GST改变无相关性。结论 :藏红花红O肾损家兔血清及尿GST及其不同亚型水平的改变 ,提示GST可作为早期诊断肾功能受损的指标 。

小鼠血清GST试验的正常值范围及其评价

报告谷胱甘肽Ｓ－转移酶（ＧＳＴ）诊断试验在健康小鼠血清中的分布和正常参考值，并应用临床流行病学方 法对血清ＧＳＴ诊断试验进行评价。结果表明，小鼠血清 ＧＳＴ活性呈对数正态分布，正常值范围为 １２～６２ｍｍｏｌ·ｍｉｎ－１· Ｌ－１。 在化学肝毒物溴苯所致小鼠急性肝损害时，血清ＧＳＴ诊断试验灵敏度为８８％，特异度为７５％，准确率达９４％。

两种生化试剂测定GGT的方法对比及偏差评估

目的在全自动生化分析仪上使用国产中生北控生物科技公司和瑞士ROCHE(罗氏)公司试剂共同检测临床患者血清r-谷氨酰转移酶(r-glutamyl transferase,GGT)。比对国产试剂与国际试剂的准确性和可靠性。方法依据原美国临床和实验室标准化委员协会(CLSI)EP9-A文件要求,每天随机抽取临床样本8份,分别用两种试剂共同测定5 d,以中生北控试剂为实验方法,瑞士ROCHE试剂为对比方法,共测定40份新鲜的患者血清GGT,然后对结果进行分析。结果经统计学分析,两种试剂测定的血清GGT结果的相关系数为0.999 3,无方法间的离群点,测定结果的偏差在允许误差范围内。结论经过方法对比及偏差评估确定在本实验室,用中生公司的GGT试剂与罗氏公司生产的GGT试剂盒对比,符合临床要求。

非酒精性脂肪性肝病患者胰岛素抵抗与血清铁蛋白、γ-谷氨酰转肽酶的关系

目的了解非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)患者胰岛素抵抗(insulin resistance,IR)与血清铁蛋白(serum ferritin,SF)及γ-谷氨酰转肽酶(γ-glutamyl transferase,GGT)的关系。方法选取108例NAFLD患者及80名健康体检者分别纳入NAFLD组及对照组。所有受试者分别检测体质量指数(BMI)、血压、血脂、ALT、AST、GGT、SF、空腹血糖(FPG)及空腹胰岛素(FINS)水平,稳态模型计算胰岛素抵抗指数(HOMA-IR)。结果 NAFLD组BMI、TG、LDL-c、GGT、SF、FINS、HOMA-IR均高于对照组(P<0.05),而HDL-c则低于对照组(P<0.05)。HOMA-IR与SF、GGT、LDL-c、BMI呈正相关(P<0.05),与HDL-c呈负相关(P<0.05)。多元逐步回归分析显示,SF、GGT、LDL-c及HDL-c是IR的主要危险因素(P<0.05)。结论 NAFLD患者血清SF、GGT及LDL-c水平升高而HDL-c水平下降,SF、GGT、LDL-c及HDL-c的变化是IR程度的主要影响因素。

乙型慢活肝血清SOD与GST测定的临床意义

分别测定30例正常人及34例乙型慢活肝活动期及静止期的SOD、MnSOD、MDA及GST的血清含量。结果慢活肝活动期与正常人及静止期病人比较均有显著差异,说明乙型慢活肝病人的SOD、MnSOD、MDA的血清含量,与病情严重程度一致。血清GST活性与SOD有明显相关性,显示了GST在反应肝细胞损伤程度上的敏感性。

血浆GGT水平与PCI术后支架内再狭窄的相关性研究

目的:观察PCI术后血浆GGT水平与支架内再狭窄的相关性。方法:选择70例支架植入术后8个月复查冠脉造影示无支架内再狭窄患者为对照组(A组),60例支架内再狭窄患者为再狭窄组(B组)(狭窄程度≥50%),采用标准方法测定其血浆GGT水平及相关生化指标,并对血浆GGT与再狭窄进行偏相关分析及多元逐步回归分析。结果:①血浆GGTB组明显高于A组(P<0.05);多元线性回归分析:血浆GGT与CRP水平的升高及ALP水平的降低能独立预测PCI术后支架内再狭窄(P<0.05)。结论:血浆GGT水平对预测支架内再狭窄有一定意义。

超声内镜联合ALP、GGT在诊断胆总管结石自发排石中的应用研究

目的探讨超声内镜(EUS)联合血清碱性磷酸酶(ALP)和y谷氨酰转移酶(GGT)在诊断胆总管结石自发排石中的价值。方法回顾性分析安徽医科大学第--附属医院2017年9月~2021年7月收治住院的诊断胆总管结石患者97例,所有患者均通过影像学等检查首诊为胆总管结石,入院拟接受内镜逆行胰胆管造影(ERCP)手术。入院时采集人选者空腹静脉血,测定ALP、GCT水平,并在术前复查此两项指标并行EUS检查。患者经ERCP治疗明确取出结石判定为阳性胆总管结石;EUS诊断为胆总管结石但ERCP未发现结石,EUS检查未发现结石,并且随访期间无胆道症状、复查影像学未发现结石均判定为自发排石。观察患者EUS、ALP和GGT结果,评估EUS、ALP和GGT诊断胆总管结石自发排石的灵敏度和特异度。结果ROC曲线分析显示,ALP和GGT检测诊断胆总管结石的ROC曲线下的面积分别为0.790和0.756,ALP灵敏度和特异度分别为50%和93.3%,GGT为90.38%和62.22%,EUS为96.1%和86.7%。结论ALP、GGT检测可以预测患者可能出现排石,而EUS检查可以较准确判定自发排石,三者联合可以更好的判断胆总管结石自发排石的发生,避免了临床不必要的有创手术,减少了患者的身体创伤及医疗费用。

右美托咪啶静脉泵注对CPB下瓣膜置换患者NAMPT、SACE的影响

目的探讨右美托咪啶静脉泵注对心肺转流(cardio pulmonary bypass,CPB)下瓣膜置换患者血管紧张素转换酶(serum angiotensin converting enzyme,SACE)、尼克酰胺磷酸核糖转移酶(Nicotinamide phosphoribosyl transferase,NAMPT)的影响。方法选取择期进行CPB下心脏瓣膜置换术患者100例,按照数字随机表法分为对照组和观察组,每组50例。2组患者均使用相同麻醉诱导方法,进行瓣膜置换术,其中观察组患者在术中静脉泵注右美托咪定。分别在麻醉诱导后(T1)、CPB开始后30 min(T2)、CPB结束时(T3)、CPB结束后2 h(T4)检测2组患者TNF-α、IL-6水平、血糖、胰岛素和胰岛素敏感指数ISI、OI、RI、NAMPT、SACE水平以及不良反应发生情况。结果 T1时2组患者的TNF-α、IL-6水平差异无统计学意义(P> 0. 05),T2、T3、T4时两项指标水平均显著升高且观察组TNF-α、IL-6水平显著低于对照组(P <0. 05)。T1时2组患者血糖、胰岛素水平以及ISI差异无统计学意义(P> 0. 05),T2、T3时血糖、胰岛素水平均显著升高观察组显著高于对照组(P <0. 05),T2、T3时2组ISI显著下降观察组显著低于对照组(P <0. 05)。T1时间时2组患者的OI、RI水平以及NAMPT、SACE水平差异无统计学意义(P> 0. 05),T2、T3时间两组患者OI均显著降低,RI以及NAMPT、SACE水平显著升高(P <0. 05),观察组OI显著高于对照组,观察组R突以及NAMPT、SACE水平I显著低于对照组(P <0. 05)。2组患者均未出现低血压和心动过缓等不良反应。结论右美托咪啶静脉泵注对CPB下瓣膜置换患者,可有效抑制炎性反应,调节NAMPT、SACE水平,增加胰岛素敏感性,降低血糖,保护肺功能。

口腔白斑患者的免疫球蛋白及其与S-谷胱苷肽转移酶、白细胞介素-2的关系

目的 探讨口腔癌前病变及口腔癌变患者的血清免疫球蛋白 (Ig)、s -谷胱苷肽转移酶 (s -GST)及白细胞介素 - 2 (IL - 2 )值的变化。方法 临床白斑患者 30例、口腔鳞癌患者 30例及正常人群 30例全部进行血清Ig、s -GST、IL - 2检测。结果 口腔癌前病变患者与口腔癌变患者的血清Ig、s -GST及IL - 2值之间无显著差异。结论 血清Ig、s-GST及IL - 2值对检测口腔癌前病变转为早期癌无特殊意义。